Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).

Jean-Sébastien Frenel,Jae Weon Kim,Dominique Berton,Rebecca Asher,Laura Vidal,Patricia Pautier,Jonathan A. Ledermann,Richard T. Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Sandro Pignata,Nicoletta Colombo,Tjoung-Won Park-Simon,Kenji Tamura,Gabe S. Sonke,Elizabeth S. Lowe,Alison E. Freimund,Chee Khoon Lee,Eric Pujade Lauraine

Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).

2020

6070Background: Olaparib maintenance is a standard treatment of BRCA1/2 mutated platinum-sensitive recurrent EOC. Despite improvement in PFS, olaparib (O) resistance often occurs and the optimal ma...

Keywords:

Oncology
Olaparib
epithelial ovarian cancer
Pathology
Internal medicine
platinum sensitive
Medicine
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations